East China Pharmaceutical announced the Phase II important results of the innovative GLP-1/GIP dual-target long-acting stimulant HDM1005 injection for the treatment of type 2 diabetes.

According to the news from East China Pharmaceuticals, recently, HDM1005, an innovative dual-target long-acting agonist for the human GLP-1 receptor and GIP receptor developed by Hangzhou Zhongmei Huadong Pharmaceuticals, a wholly-owned subsidiary of East China Pharmaceuticals, has achieved positive results in Phase II clinical trials for the indication of type 2 diabetes in China. The research shows that HDM1005 demonstrates significant effects on lowering blood sugar and weight in T2DM patients, and also improves cardiovascular and metabolic related indicators such as blood pressure and blood lipids, providing comprehensive clinical benefits for patients.